Press Releases

Press Releases

Date Title and Summary Additional Formats
Jun 03, 2021 Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®
- Without an NOC, Ruzurgi ® is without a Marketing Authorization in Canada - Matter Remanded Back to Health Canada to Provide a More Transparent Record of Its Decision in Light of Firdapse ® ’s Data Protection CORAL GABLES, Fla. , June 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.
May 19, 2021 Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
CORAL GABLES, Fla. , May 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,
May 10, 2021 Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
-Firdapse® Q1 2021 Net Revenues of $30.2 Million -First Quarter 2021 GAAP Net Income of $7.7 Million ; Non-GAAP Net Income of $11.6 Million -Recently Received Orphan Drug Designation for Firdapse® in Japan - $143.3 Million in Cash and Investments and no Funded Debt at end of Q1-2021 -Catalyst to
May 03, 2021 Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021
CORAL GABLES, Fla. , May 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases,
Mar 22, 2021 Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program
CORAL GABLES, Fla. , March 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Mar 15, 2021 Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
- Firdapse ® Q4-20 Net Revenues of $31.0 Million , FY-20 Net Revenues of $119.1 Million - GAAP Net Income of $75.0 Million for Fiscal Year 2020 - $140.3 Million in Cash and Investments and No Funded Debt - Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla.
Mar 04, 2021 Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021
CORAL GABLES, Fla. , March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
Feb 22, 2021 Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021
Catalyst Supporting Facebook Live Panel on Living with a Rare Disease Hosted by The Mighty Catalyst Kicks off Rare Reason Campaign CORAL GABLES, Fla. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on
Jan 06, 2021 Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update
Company to Expand R&D Focus for Pipeline Growth to include Earlier Stage Programs and Validated Technology Platforms Firdapse® 2020 Net Revenues Estimate of approximately $118 Million ; about 16% Increase From 2019 Ended 2020 with Estimated $140 Million in Cash and Investments Company Highlights